Mindmed announces chief executive officer transition

New york, june 9, 2021 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (de: mmq) (the "company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that j.r. rahn, the company's co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, robert barrow, will assume the position of chief executive officer with immediate effect.
MNMD Ratings Summary
MNMD Quant Ranking